Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Orthopaedics
  • Orthopaedics News
  • Lorecivivint promising...

Lorecivivint promising treatment option for knee osteoarthritis, interim findings from trial reveal

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2022-12-17T09:30:33+05:30  |  Updated On 17 Dec 2022 9:22 AM GMT
Lorecivivint promising treatment option for knee osteoarthritis, interim findings from trial reveal
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • koo
  • Email

USA: Repeated injections of the lorecivivint (LOR) in knee osteoarthritis patients may slow the decline of medial joint space width, according to interim findings from a long-term extension trial released by Biosplice. "We believe these unique data highlight lorecivivint's promise to potentially provide structural benefit to the millions of patients suffering from osteoarthritis,"...

USA: Repeated injections of the lorecivivint (LOR) in knee osteoarthritis patients may slow the decline of medial joint space width, according to interim findings from a long-term extension trial released by Biosplice. 

"We believe these unique data highlight lorecivivint's promise to potentially provide structural benefit to the millions of patients suffering from osteoarthritis," commented Biosplice Chief Medical Officer, Yusuf Yazici, MD. "These latest interim results from OA-07 build upon our robust body of existing evidence, suggesting that repeat injections of LOR could provide patients and physicians with both structure-modifying and symptomatic benefits. We recently initiated our phase 3 OA-21 clinical trial and are enrolling subjects. We are excited to continue investigating LOR as a treatment option for knee OA."

OA-07 is a long-term extension trial, which enrolled patients who completed OA-11, a previous 12-month study. The primary efficacy objective of OA-07 is to measure the disease-modifying potential of lorecivivint over multiple years and injections. During the first year of the OA-07 study, patients and investigators remained blinded. Patients received injections of LOR annually, allowing Biosplice to capture both long-term and repeat-injection data for safety, efficacy, and mJSW.

Previously presented at the American Conference of Rheumatology Annual Meeting in November 2022, data for the first year of OA-07 show clinically significant improvement in mJSW relative to placebo, with an effect size of 0.13 mm in KL2 subjects. Moreover, OA-07 data demonstrate a significant improvement in WOMAC Pain and robust trends in Pain NRS (daily pain score) as well as WOMAC function in all subjects.

In the second year of the OA-07 trial, placebo subjects crossed-over to receiving LOR, although all subjects remain blinded as to whether they had previously received LOR or placebo. In subjects who have completed their second annual visit and who previously received LOR in OA-11 and OA-07, there continues to be an increase in their mJSW versus baseline. These subjects have now received three injections of LOR over three years.

Among those subjects who have completed their second annual OA-07 visit and who previously had received placebo, the introduction of LOR appears to have arrested their decline in mJSW.

Please see graphic below for the interim data generated to date.

 

Consistent with the clinical program to date, LOR continued to appear safe and well-tolerated in the recently completed studies, with no safety signals with repeat injections.

The OA-21 phase 3 clinical trial is designed as a 16-week study with a primary endpoint of Pain NRS at 12 weeks. This study will further evaluate the impact of LOR on knee osteoarthritis pain and function and has been designed to enroll the less structurally damaged patient population that has shown consistent responses across Biosplice's phase 2 and phase 3 clinical trials.

 

lorecivivintOsteoarthritisKnee Osteoarthritisplaceboknee osteoarthritis pain
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Before Joining Medical Dialogues, he has served at important positions in the medical industry in India including as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils in India. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X